Finance Watch: Public Markets Open Back Up For Biopharma Offerings
AN2 Launches First US IPO In More Than A Month
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
You may also be interested in...
Rather than making smaller investments in a larger number of areas, Orion is putting its research euros into oncology and pain management and pulling its Parkinson’s and Alzheimer’s projects, as well as its rare disease programs.
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement.